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Medical Marijuana Policy Reform Reaches
Florida: A Scoping Review
_______________________________________________________________________________
Khadesia Howell, MPH; Alexandria Washington, MPH; Paula M Williams, MPH; Arlesia L
Mathis, PhD; John S Luque, PhD, MPH
________________________________________________________________________________
ABSTRACT
Background: Florida became the first state in the U.S. South to legalize the use of medical marijuana to treat a variety
of health conditions including chronic pain, epilepsy, and spasticity symptoms from multiple sclerosis. While there are
over 200,000 medical marijuana patients in Florida, there remain financial, psychological, and insurance coverage
barriers which reduce access for many patients. Purpose: This scoping review, with a focus on state health policy, first
describes some clinical studies examining the therapeutic benefits of medical marijuana. Next, there is a discussion of
the Florida regulatory environment and major legislation. Also, the review describes how the current Florida policy
landscape presents challenges for physicians and patients. Methods: A scoping review of the literature was conducted in
PubMed and Google Scholar using the search terms, “medical marijuana” and “medical cannabis” to identify research
articles, newspaper reports, and government documents. The purpose of the review was to identify research investigating
the therapeutic efficacy of medical marijuana and state policies affecting physician practice. Results: The review
concluded there was general scientific consensus of therapeutic benefits for patients, especially for chronic pain, from
the use of medical marijuana. The review also identified several barriers for physicians and patients around cost, stigma,
and lack of insurance coverage which constrains use and access. Discussion: The review discusses several directions for
future medical marijuana policy and research with the aim to improve therapeutic benefits for Florida patients.
Howell K, Washington A, Williams PM, Mathis AL, Luque JS. Medical marijuana policy reform reaches Florida:
A scoping review. Florida Public Health Review. 2019;16:128-136.
____________________________________________________________________________________________
BACKGROUND
Marijuana, the dried leaves and flowers of the herbal
plant Cannabis sativa, is the most commonly used
illicit drug in the United States.1 Since 1970, marijuana
has been classified as a Schedule I substance under the
Controlled Substances Act and applied by the U.S.
Drug Enforcement Agency (DEA). This class of
drugs, substances, and chemicals are defined as those
with no “currently accepted medical use and high
potential for abuse.”2 However despite the federal ban,
there are 33 legal medical marijuana states dating back
to 1996, and 10 legal recreational marijuana states
dating back to 2012.3 Florida became the first state in
the U.S. South to allow residents to use medical
marijuana following the passage of Ballot Amendment
2 in 2016.4 Medical marijuana, for the purposes of this
review, refers to botanical cannabis, rather than to any
marijuana-derived pharmaceutical product.
Despite the classification of marijuana as an illegal
substance under federal law, a growing body of
research has suggested marijuana has therapeutic
benefits for a variety of health conditions. Clinical
studies suggest medical marijuana may reduce
neuropathic pain, nausea and vomiting due to
Florida Public Health Review, 2019; 16, 128-136.
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chemotherapy, spasticity from multiple sclerosis
(MS), intraocular pressure, and increase appetite.5,6
Because of the Schedule 1 classification, scientific
studies of marijuana have been extremely limited in
the U.S., yet researchers in Canada and Europe have
conducted clinical trials of cannabis-derived drugs
such as Sativex®, which addresses neuropathic pain in
MS patients.7,8 Sativex® contains a 1:1 ratio of Delta9-tetrahydrocannibinol (THC) to cannabidiol (CBD),
which reduces some of the potential negative side
effects of higher THC levels.9 To date however, the
Food and Drug Administration (FDA) has only
approved the use of marijuana for two rare and severe
forms of epilepsy, which also places limits on the
ability to cover the drug under health insurance
plans.10 The FDA has approved one cannabis-derived
and three cannabis-related pharmaceutical drug
products.11 One of these products is Epidiolex®
(derived from CBD), an oral solution for the treatment
of seizures associated with severe forms of epilepsy.
Another drug product is Cesamet® with the active
ingredient nabilone, a synthetic analogue of THC, to
treat nausea and vomiting associated with cancer
chemotherapy. Marinol® and Syndros® are also
Page 128
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FDA-approved and contain the active ingredient
dronabinol, another synthetic form of THC, which is
an antiemetic used to increase appetite in patients with
the human immunodeficiency virus and to help
patients experiencing wasting from cancer
chemotherapy.
Marijuana contains over 100 different chemicals
which are classified as cannabinoids, chemicals which
can be used for medicinal purposes when using the
whole unprocessed marijuana plant or its essential
extracts.12 The two most well-known chemicals of this
class are THC and CBD. THC content in recreational
marijuana in the U.S. nearly doubled between 1997
and 2006, from 4.5% to 8.5%, which is notable
because 1) higher THC levels are more likely to

produce adverse psychological effects in naïve users,
and 2) past recreational users who transition to
medical users may be accustomed to higher THC
levels.13 Depending on the strain, a higher percentage
of CBD attenuates the risk of using high THC
marijuana.14 Despite what is known about THC:CBD
ratio combinations and their differential effects,
medical marijuana laws do not provide guidance on
THC levels for medical-grade marijuana.15 Figure 1
below illustrates how a drug company or medical
marijuana treatment center (MMTC) might explain
how the chemicals provide therapeutic benefits to
patients. By modifying these ratios, individualized
treatment might be offered to patients with a variety of
mixture types available.

Figure 1. Example of educational graphic to explain therapeutic benefits of THC and CBD

Because of the trend of legalizing the use of medical
marijuana in more than half of all states, some medical
organizations support reclassification of marijuana at
the federal level as a Schedule II controlled substance.7
Furthermore, the medical marijuana treatment
industry, pharmaceutical companies, and academia are
invested in continuing the study of medical marijuana,
as any other medical therapy has been studied, which
would result in the drug being removed from the
Florida Public Health Review, 2019; 16, 128-136.
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Schedule 1 category if the drug demonstrated
effectiveness for certain medical conditions in
placebo-controlled trials. However, most research has
been limited to retrospective cohort studies, case
studies, or observational studies creating a conundrum
for developing an evidence base.14 Conducting more
clinical studies would help inform physicians on
proper dosing of cannabis-based medicines, yet the
ability to conduct these studies is hampered by current
Page 129
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legal and policy barriers, leading to a Catch-22. More
research is needed to measure the therapeutic benefits
for patients how cannabinoids affect human health.
This review begins with describing clinical studies on
the therapeutic benefits of medical marijuana. This is
followed by a discussion of the Florida regulatory
environment and existing legislation which govern
physician practice. The review also discusses barriers
to patient access and health disparities. Marijuana, like
any other drug therapy, involves both risks and
benefits. There are potential harms related to chronic
marijuana use such as the increased risk of motor
vehicle crashes, worsening of schizophrenia or other
related mental disorders in some individuals, and
increased severity of respiratory symptoms, among
other risks.17 It is with these caveats that this review
proceeds to review the literature regarding the
therapeutic benefits of medical marijuana and the
current policy landscape in Florida.
METHODS
A scoping review of the literature was conducted in
PubMed and Google Scholar using the search terms,
“medical marijuana” and “medical cannabis” to
identify research articles for this review.18 In addition,
an internet search was conducted using the search
terms, “Florida medical marijuana law” to identify
articles in newspapers and law journals for further
information about challenges related to the
decriminalization of medical marijuana in the state.
The results of the literature search were compiled into
an Endnote database. The purpose of conducting the
scoping review was to document recent evidence on
the therapeutic benefits of medical marijuana and
identify challenges for physicians and patients in the
context of decriminalization in Florida.
RESULTS
The results from the literature search were comprised
of primarily peer-reviewed articles (83 articles). The
peer-reviewed articles were published between 2005
and 2019, with the bulk of the articles published since
2014 (74 articles). The articles primarily reported
original research, but the literature search also
included 14 literature review articles. Other document
sources included government websites, Florida
newspaper articles, Florida Bar Journal articles,
Florida statutes, and consensus study reports (15
documents). The Physician Certification Pattern
Review Panel Annual Report provided detailed data
on medical marijuana recommendation patterns in
Florida and information on certifying conditions.19
However, the report does not contain summary
demographic information on medical marijuana
patients.
Use of Marijuana in Modern Medicine

Florida Public Health Review, 2019; 16, 128-136.
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There is a growing interest in the research and use of
medical
marijuana
and
marijuana-based
pharmaceuticals for the treatment and management of
a variety of conditions. After a thorough review of all
medical marijuana clinical studies by the National
Academy of Sciences, Engineering, and Medicine, the
panel concluded there was conclusive evidence that
cannabis-based medicines are effective for the
treatment of chronic pain, chemotherapy-induced
nausea and vomiting, and symptoms of spasticity
symptoms in MS patients.17 In a study by Crowell20 the
most common reasons for indicating the use of
medical marijuana among a group of patients in New
Jersey were intractable skeletal spasticity, chronic
pain, MS, and inflammatory bowel disease. Medical
marijuana is generally indicated to be beneficial for
the treatment of several conditions such as chronic
non-malignant pain, poor appetite, nausea, depression,
anxiety, arthritis, bruxism, chemotherapy-induced
nausea and vomiting, chronic fatigue, depression,
diabetes symptoms, spasticity from MS, epileptic
seizures, and intestinal disorders.21
While medical marijuana has many potential uses, the
primary therapeutic use is to treat chronic pain in
adults. Chronic non-cancer pain is the most commonly
cited use of medical marijuana in the U.S., Canada,
and the Netherlands.22 While there is the general
public perception that marijuana may be used to treat
pain, to date, few large randomized controlled trials
have been conducted to test this assumption. A
systematic review of 15 trials on the effect of medical
marijuana on non-cancer pain reported significant
improvements in patients with neuropathic pain, and
moderate improvement in fibromyalgia and
rheumatoid arthritis.23 Another systematic review of
24 randomized controlled trials provided some
evidence for the effectiveness of medical marijuana in
the treatment of chronic pain conditions such as
arthritic pain, headache, neuropathic pain, and visceral
pain, especially by inhalation.24 However, more
research is needed to establish the efficacy of different
formulations of medical marijuana for pain treatment.
Chronic pain is a persistent and widespread public
health problem, and opioids are commonly prescribed
to treat pain. An Institute of Medicine report listed
several causes of chronic pain prevalence which
included: 1) rising obesity; 2) increase in number of
cancer survivors; 3) complications from surgical
procedures; and 4) musculoskeletal disorders in older
adults.25 Medical marijuana is considered a safer
alternative than opioids for patients who may be at risk
for addiction and overdose. One national study
identified that in states with medical marijuana laws
and prescription drug monitoring programs, opioidrelated deaths substantially decreased.26 Another
national study reported that in states with medical
marijuana laws, the opioid overdose rate decreased
Page 130
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over time, from 20% in the first year to 33% by the
sixth year since enactment of the laws.27 Populationwide opioid overdose deaths have decreased in states
that have not stringently regulated the operation of
medical marijuana dispensaries and are permitted
more latitude in dispensing practices.28-32 For many
pain patients, medical marijuana may be a safer
alternative than prescription opioids.
Methods of Consuming Medical Marijuana
There are different ways for patients to use medical
marijuana effectively. Marijuana is primarily inhaled,
but other modes of use include ingestion of food
prepared with marijuana oils (i.e., edibles), and topical
applications. In Florida, products available for
purchase include vape pens, vaporizers, capsules, oral
syringes, drops, oils, topical creams, and smokable
marijuana.33 There is also distinction between lowTHC cannabis, defined as products with less than
0.8% of THC and more than 10% of CBD, compared
with medical marijuana, which encompasses all forms
of the plant – including low-THC marijuana –
dispensed by a MMTC to qualified patients.
Qualifying Conditions for Medical Marijuana in
Florida
In July 2014, the Florida Legislature passed the
Compassionate Medical Use Act. In January 2015
qualified physicians were permitted to issue patient
orders for low-THC cannabis under limited
conditions, and in August 2016 the first low-THC
cannabis and medical marijuana were made available.
In February 2017, Medical Marijuana Use Registry
identification cards were issued to patients, and
qualified physicians could issue these cards to
patients. In March 2019, smokable marijuana became
available for qualified patients, which was previously
not permitted.34 Once a patient’s identification card
application is approved, the patient can fill an order at
one of the licensed MMTCs following the physician’s
recommendation.
The following medical conditions qualify a patient to
receive medical marijuana: cancer, epilepsy,
glaucoma, HIV-positive status and AIDS, posttraumatic stress disorder (PTSD), amyotrophic lateral
sclerosis (ALS), Crohn’s Disease, Parkinson’s
Disease, MS, terminal conditions, and chronic nonmalignant pain.19 As of February 15, 2019, 2,082
physicians had completed the required training course
on medical marijuana, which needs to be renewed
every two years.35 As of April 2019, there were 114
licensed MMTCs. In 2018 (January through
September), 1,070 physicians issued 174,254
certifications to 136,274 patients for low-THC
cannabis and medical marijuana.19
Medical marijuana is currently being used primarily
for pain management both in Florida and nationwide.
Out of all the certifications in Florida, the top five
conditions included: chronic non-malignant pain
Florida Public Health Review, 2019; 16, 128-136.
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(27.7%), qualifying medical conditions other than
chronic non-malignant pain or terminal conditions
(27.3%), PTSD (23.6%), cancer (9.8%), and epilepsy
(2.5%). There have been some advances to understand
dispensing practices based on nationwide patient
registry information. Analysis of state registry data
nationwide for medical marijuana use (1999-2017)
reported that chronic pain was the most common
condition indicated (62%), followed by spasticity from
MS, chemotherapy-induced nausea and vomiting,
PTSD, and cancer.3 To bolster the case for responsible
recommendations, over 85% of qualifying conditions
(chromic pain, chemotherapy-induced nausea and
vomiting, and spasticity from MS) were identified by
the 2017 National Academies report as conditions with
either conclusive or substantial evidence of
therapeutic effectiveness.17
Florida Policy for Physicians
The Florida Department of Health Office of Medical
Marijuana Use maintains a list of physicians who are
permitted to order low-THC cannabis, medical
marijuana, and drug delivery devices. Under current
law, physicians certified to work in Florida are
protected against criminal penalties for recommending
medical marijuana to patients with qualifying
conditions within specified guidelines. According to
the law, a physician is authorized to order medical
marijuana to treat patients suffering from a qualifying
condition if the physician holds an active, unrestricted
license as a physician (f.s. 458) or osteopathic
physician (f.s. 459) and has successfully completed
training.34 Training includes a two-hour course, per
qualifying condition, and passing of an exam issued by
their respective certifying Boards (Florida Board of
Osteopathic Medicine or Florida Board of Medicine)
each year. The $250 course covers information on
rules and regulations, allowable conditions and
delivery mechanisms, legal restrictions, and decision
making for physicians on patient eligibility.36
Certifying Boards maintain documentation on how
many patients are certified, the type of delivery
mechanism used by patients, and the quantity of
medical marijuana recommended. For certifying
patients, physicians may only issue a certification with
an in-person patient visit, and certifications cannot be
issued through a telemedicine consultation. Qualified
physicians are only able to issue three 70-day supplies
in each consultation. Physicians are required to
maintain a treatment plan that includes the dosage,
route of administration (oral, skin, etc.), planned
duration, monitoring of symptoms or other indicators
of toleration. A recommending physician who violates
these guidelines commits a first-degree misdemeanor
punishable by fines up to $1,000 (f.s. 775.083(1)(d))
or imprisonment not exceeding one year (f.s.
775.082(4)).34
Clinical Challenges
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A commentary by a physician group on their clinical
experience in certifying patients for medical marijuana
illustrates the difficulties physicians may face to meet
the needs of their patients.37 They conducted a chart
review of 166 patients in their practice in Chicago,
Illinois and identified five factors which especially
posed challenges for their practice. These included the
following:
1. Suboptimal knowledge of effectiveness,
dosage, delivery mechanism, indications, and
drug interactions;
2. No educational standards for dispensary and
medical staff training;
3. Poor communication and coordination of
patient care;
4. Challenges with supply of dosing options;
and
5. Access barriers for those wanting medical
marijuana treatment.
Areas for improvement were identified in the
commentary. For example, in terms of dispensary
staff, there was a shortage of pharmacists and other
trained staff, so if more pharmacists were available,
they would be able to help with issues regarding
potential drug interactions and dosing. Another issue
involves the number of medical marijuana choices
available for dosing (e.g., edibles, patches, oils,
creams, inhalation). This menu of options can create
confusion for physicians and patients in terms of
dosing formulas to best address patient’s symptoms
while minimizing side effects. In the commentary, the
authors recommended better data-driven guidelines on
these issues and potential drug interactions with other
medications (e.g., opioids, benzodiazepines, and
antidepressants).37 There is also the important role for
medical marijuana cultivators and dispensaries to only
supply the most effective medical marijuana
preparations to solve issues of quality control, supply
and product demand.
Barriers for Access to Medical Marijuana
Because of the current regulatory environment, there
are barriers to medical marijuana access for patients.
These include patient hesitancy to discuss medical
marijuana options with physicians as well as
paperwork burden and regulatory hurdles to become a
qualified physician in order to start issuing
certifications.38 Studies have reported that medical
marijuana use is more predominant among European
Americans and less likely among Black, Latino, Asian
and foreign-born individuals.6,39 There are various
reasons for the discrepancies in access such as
disposable
income,
stigma,
and
physician
preferences.39,40 Patients might feel stigma in asking
their personal physician to issue a certification for
medical marijuana use, or their personal physician
might not be certified to recommend medical
marijuana.38 A review article focused on barriers to
Florida Public Health Review, 2019; 16, 128-136.
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medical marijuana access reported that medical
marijuana use is more common among individuals
who are employed, earn high incomes, and have health
insurance.39
In addition to costs such as co-payments for the
doctor’s visit, there are fees associated with obtaining
a medical marijuana card. In Arizona, there is a $150
initial and renewal registration fee for the state’s
program.39 In Florida, there is no insurance coverage
for medical marijuana, and private insurers cite
reasons for non-coverage including lack of FDA
approval and the federal classification of marijuana as
a Schedule 1 drug. For Florida residents, patients first
need a medical consultation which costs $250 or more
to be certified as a medical marijuana patient;
however, the medical consultation cost may vary.41
Next, there is an initial $75 application fee for the
identification card, which is valid for one year. Costs
for the product which is obtained at the dispensary
vary depending on the medical marijuana delivery
option. If the patient purchases their own vaporizer to
use with pre-filled cartridges, the unit costs between
$100-$300 and cartridges cost between $35 and $60
depending on the amount and type or strain. Patients
must be recertified every seven months which incurs
another physician visit. Therefore, total costs for the
first year of use can easily exceed $600, which could
be a burden for low-income patients.
Physicians certified to recommend medical marijuana
can charge what they deem as reasonable for a
consultation. Furthermore, the cost of medical
marijuana can range from $50 to $150 for certain
amounts at dispensaries. Currently, dispensaries in
Florida are not equally distributed throughout the
state, thus reducing access to some populations,
especially in rural areas. This may exacerbate
equitable access and contribute to missed economic
activity for Florida. In addition to the direct economic
benefits for Florida from increased tax revenues which
are redistributed to healthcare, there are other benefits
of medical marijuana. These include reducing arrests
for marijuana possession, which disproportionately
affect minority communities, and sanctioning the
medical and compassionate use of medical marijuana.4
DISCUSSION
This review summarized numerous recent clinical
studies and concludes that there is evidence that
medical marijuana provides therapeutic benefits to
patients for a variety of health conditions, but
particularly for chronic pain patients, cancer patients
with chemotherapy-induced nausea and vomiting, and
MS patients with spasticity symptoms. However, there
is a need for more controlled studies, especially in the
areas of cancer pain, intestinal disorders, and mental
health. Since medical marijuana is being
recommended for patients suffering from PTSD and
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and anxiety, but they had received the
recommendation from friends or family rather than a
medical provider.44 The study highlighted the need for
more patient and physician communication on the
potential benefits of medical marijuana for some
cancer patients. Future research in medical marijuana
will hopefully lead to improved therapeutic benefits
for patients and greater understanding of the effects of
cannabinoids on human health.
Conclusions
This scoping review has identified ongoing and past
research efforts to demonstrate the therapeutic benefits
of medical marijuana and points to some possible
areas of investigation for health policy research.
Because Florida law keeps medical marijuana in the
health domain and the drug has not been
decriminalized, regulatory activities remain in the
Florida Department of Health instead of other agencies
which regulate alcohol and tobacco, as was done in
Colorado for example.45 One of the greatest challenges
in Florida is the need for quality physician training and
for more physicians to receive certification to improve
physician/patient communication and patient
education on this emerging therapy option. Moreover,
there is an important role for public health in policy
development around excise and sales taxes and
collecting population-wide state data on marijuana use
ahead of the possibility of expanded decriminalization
policies.

generalized anxiety disorder, more research is needed
to demonstrate improvement in mental health
outcomes for these debilitating conditions. Since this
is a scoping review, there was no attempt to assess the
quality of the controlled studies identified and
included, therefore there are limitations in terms of
recommendations for policy or practice since the rigor
of the clinical studies was not assessed.42
In terms of the Florida regulatory environment, some
of the laws governing dispensaries and MMTCs are
currently experiencing legal challenges, so there could
be future changes in the number of MMTCs allowed
to operate in Florida for example, which is currently
capped. Increasing the number of dispensaries that
could reach into rural areas of the state would increase
access. In the current policy environment, challenges
also remain in terms of physician education and
reducing stigma among healthcare providers to
become a certifying physician. From the physician
perspective, there is stigma from becoming qualified
to provide patients with medical marijuana
certifications. Since prescribing medical marijuana is
illegal under federal law, according to an investigative
report, physicians fear they might be at risk of being
blacklisted by hospital systems, nursing homes, or
hospices, which rely on Medicaid and Medicare
reimbursement funds; moreover, another issue which
might contribute to stigma occurs when physicians
with poor reputations are filling the void to work in
MMTCs.43
In the research arena, challenges remain to provide the
funding necessary to establish the research
infrastructure at Florida’s public universities and
research institutes given the existing federal policies
and shifting priorities for state research dollars.
Currently, there is limited research on medical
marijuana being conducted in Florida. One recent
study funded by the Florida legislature with glioma
patients at Moffitt Cancer Center in Tampa, Florida
reported that only a third of patients were using
medical marijuana and received benefits from its use
for symptoms including pain, nausea, poor appetite,
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